Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR)

Abhishek Sharma, Sunny Goel, Carl J. Lavie, Armin Zadeh, Debabrata Mukherjee, Jason Lazar

Research output: Contribution to journalArticle

Abstract

Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

Original languageEnglish (US)
Pages (from-to)467-473
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume39
Issue number4
DOIs
StatePublished - May 1 2015

Fingerprint

Therapeutics
Guidelines
Hemorrhage
Transcatheter Aortic Valve Replacement

Keywords

  • Dual antiplatelet therapy (DAPT)
  • Transcatheter aortic valve replacement (TAVR)

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR). / Sharma, Abhishek; Goel, Sunny; Lavie, Carl J.; Zadeh, Armin; Mukherjee, Debabrata; Lazar, Jason.

In: Journal of Thrombosis and Thrombolysis, Vol. 39, No. 4, 01.05.2015, p. 467-473.

Research output: Contribution to journalArticle

Sharma, Abhishek ; Goel, Sunny ; Lavie, Carl J. ; Zadeh, Armin ; Mukherjee, Debabrata ; Lazar, Jason. / Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR). In: Journal of Thrombosis and Thrombolysis. 2015 ; Vol. 39, No. 4. pp. 467-473.
@article{f24e8e31bb534a4cb67f1b65067324f5,
title = "Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR)",
abstract = "Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.",
keywords = "Dual antiplatelet therapy (DAPT), Transcatheter aortic valve replacement (TAVR)",
author = "Abhishek Sharma and Sunny Goel and Lavie, {Carl J.} and Armin Zadeh and Debabrata Mukherjee and Jason Lazar",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s11239-014-1118-x",
language = "English (US)",
volume = "39",
pages = "467--473",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR)

AU - Sharma, Abhishek

AU - Goel, Sunny

AU - Lavie, Carl J.

AU - Zadeh, Armin

AU - Mukherjee, Debabrata

AU - Lazar, Jason

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

AB - Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

KW - Dual antiplatelet therapy (DAPT)

KW - Transcatheter aortic valve replacement (TAVR)

UR - http://www.scopus.com/inward/record.url?scp=84939896870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939896870&partnerID=8YFLogxK

U2 - 10.1007/s11239-014-1118-x

DO - 10.1007/s11239-014-1118-x

M3 - Article

C2 - 25103613

AN - SCOPUS:84939896870

VL - 39

SP - 467

EP - 473

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 4

ER -